Dr. Frederique Menzaghi is one of the founders of Cara Therapeutics, a provider of novel drugs for the treatment of human diseases associated with pain and inflammation. Dr. Menzaghi has also been serving as Cara’s chief scientific officer since 2019, and its senior vice president of research and development since 2017.
Dr. Menzaghi leads preclinical research and pruritus clinical programs, and she brings more than two decades of expertise in management and drug development in biotechnology.
Her expertise in research and development includes a proven track record of leading drug discovery programs for obesity, pain, inflammation, cognitive, psychiatric, and neurological disorders.
Prior to Cara, Dr. Menzaghi served as vice president of pharmacology & business development for Psychogenics Research, director of in vivo pharmacology for Arena Pharmaceuticals, and director of a research lab at SIBIA Neurosciences.
Dr. Menzaghi also has extensive corporate experience, partnering with pharmaceutical companies such as Merck, Eli Lilly, and J&J.
She holds a graduate degree in clinical psychology from Ecole des Mines de Nancy (University of Nancy, France), a Ph.D. in neurosciences from the University of Louis Pasteur, Strasbourg, and she conducted post-doctoral research at the Scripps Research Institute in San Diego. Dr. Menzaghi has authored numerous peer-reviewed publications, book chapters, and presentations, and she is a named inventor on multiple patents.
How do I contact Frederique Ph.D. Menzaghi?
Has Frederique Ph.D. Menzaghi been buying or selling shares of Cara Therapeutics?
Who are Cara Therapeutics' active insiders?
Are insiders buying or selling shares of Cara Therapeutics?
In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 60,503 shares worth more than $33,858.03. The most recent insider tranaction occured on May, 2nd when CEO Christopher Posner sold 3,936 shares worth more than $2,952.00. Insiders at Cara Therapeutics own 3.1% of the company.
Learn More about insider trades at Cara Therapeutics. Information on this page was last updated on 5/2/2024.
